{"id":"NCT02229383","sponsor":"AstraZeneca","briefTitle":"Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glargine Compared to Placebo Added to Titrated Basal Insulin Glargine in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine With or Without Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09-06","primaryCompletion":"2016-08-29","completion":"2016-08-29","firstPosted":"2014-09-01","resultsPosted":"2017-09-18","lastUpdate":"2019-01-08"},"enrollment":464,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Exenatide","otherNames":[]},{"type":"DRUG","name":"Exenatide matching placebo","otherNames":[]}],"arms":[{"label":"Exenatide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Study D5553C00002 is a multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 3 study to compare the safety and efficacy of exenatide once weekly (EQW) added to titrated basal insulin glargine with or without metformin to placebo added to titrated basal insulin glargine with or without metformin in patients with type 2 diabetes mellitus (T2DM). Eligible patients will be randomized at Visit 5 (Day 1) to receive either EQW added to titrated basal insulin glargine, with or without metformin ≥1500 mg/day, or placebo added to titrated basal insulin glargine, with or without metformin ≥1500 mg/day, during the 28-week treatment period.","primaryOutcome":{"measure":"Change in HbA1c From Baseline to Week 28","timeFrame":"Baseline to Week 28","effectByArm":[{"arm":"Exenatide","deltaMin":-0.96,"sd":null},{"arm":"Placebo","deltaMin":-0.22,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":123,"countries":["United States","Hungary","Poland","Romania","Slovakia","South Africa"]},"refs":{"pmids":["32306296","29473704"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":231},"commonTop":["Urinary tract infection","Nausea","Blood creatine phosphokinase increased","Injection site nodule"]}}